Sehr geehrte Damen und Herren,

hiermit laden wir Sie herzlich ein zu dem Vortrag:

"Use of short-term endpoints in multi-stage designs"

von

Dr. Cornelia Ursula Kunz, University of Warwick (UK)

am Montag, 20.01.2014, 16.15 Uhr

im DKFZ, ATV-Raum, Im Neuenheimer Feld 242, 69120 Heidelberg

Phase II oncology trials are conducted to evaluate whether the tumour activity of a new treatment is promising enough to warrant further investigation. The most commonly used approach in this context is a two-stage singlearm design with binary endpoint. As for all designs with interim analysis, its efficiency strongly depends on the relation between recruitment rate and follow-up time required to measure the patients’ outcome. Usually, recruitment is stopped when the sample size of the first stage is achieved and is continued not before the outcomes of all these patients are available. This may lead to a considerable increase of the trial length and with it to a delay in the drug development process. We propose a design where an intermediate endpoint is used in the interim analysis to decide whether or not the study is continued with a second stage. Optimal and minimax versions of this design are derived. The characteristics of the proposed design in terms of type I error rate, power, maximum and expected sample size as well as trial duration are investigated. Guidance is given how to select the most appropriate design.

Alle Interessenten sind herzlich eingeladen!

GEZEICHNET: BECHER, DICKHAUS, KIESER, KNAUP, KOPP-SCHNEIDER, WELLEK

Organisation: Birgit Schleweis
Institut für Medizinische Biometrie und Informatik, Im Neuenheimer Feld 305, 69120 Heidelberg, Tel. 06221/56-4142
Möchten Sie die wöchentliche Ankündigung der Vorträge (ggf. mit Vortragszusammenfassung) per E-Mail zugeschickt bekommen, so senden Sie bitte eine Nachricht an: schleweis@imbi.uni-heidelberg.de